New clinical data confirms Bmab 1200, a biosimilar to ustekinumab, offers equivalent efficacy and safety for treating ...

UK neurologists release new guidelines for JC virus testing in patients using the natalizumab biosimilar Tyruko, addressing ...

A recent study reveals global regulatory inconsistencies in biosimilars, urging convergence to enhance access and savings for patients and health care systems.

FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for ...

A new study confirms that biosimilar ranibizumab matches innovator Lucentis in treating myopic choroidal neovascular membrane ...

A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings. Patients with inflammatory bowel disease (IBD) who transitioned from ...

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults. Infliximab biosimilar ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...

Bevacizumab biosimilars Mvasi and Zirabev provided cost savings for metastatic colorectal cancer (mCRC) treatment without compromising effectiveness. A real-world, economic evaluation based on a ...